-
Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
Ruwaard, J., l’ Ami, M. J., Kneepkens, E. L., Krieckaert, C. L. M., Nurmohamed, M. T., Hooijberg, F., van Kuijk, A. W. R., van Denderen, J. C., Burgemeister, L., Rispens, T., Boers, M. & Wolbink, G. J., 2022, (E-pub ahead of print) In: Scandinavian Journal of Rheumatology.Research output: Contribution to journal › Article › Academic › peer-review
-
Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis
l’ Ami, M. J., Ruwaard, J., Krieckaert, C. L. M., Nurmohamed, M. T., van Vollenhoven, R. F., Rispens, T. & Wolbink, G. J., 4 Jul 2019, In: Scandinavian Journal of Rheumatology. 48, 4, p. 266-270 5 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice
Layegh, Z., Ruwaard, J., Hebing, R. C. F., l’ Ami, M. J., van der Weele, W., Nurmohamed, M. T., Krieckaert, C. & Wolbink, G., 1 May 2019, In: International journal of rheumatic diseases. 22, 5, p. 869-873 5 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
